A Medical Device Daily

IMS Health (Fairfield, Connecticut), a provider of healthcare data, primarily for the pharmaceutical industry, is to be acquired by Dutch media company VNU (Haarlem, the Netherlands) in a cash-and-stock deal valued at $6.9 billion.

For VNU, the deal will add healthcare to a market intelligence mix that includes the well-known Nielsen media information and A.C. Nielsen consumer-goods information franchises. It also produces such trade publications as Billboard, Computing, Intermediair and The Hollywood Reporter.

At EUR 5.8 billion, the deal’s value nearly equals VNU’s market capitalization, which stands at about EUR 6 billion. It will offer IMS shareholders $11.25 a share in cash and 0.6 of a share of VNU stock for each IMS share held, representing a 16% premium on the U.S. firm’s average share price over the past 30 days.

“This merger of two industry leaders gives us the scale and capabilities to meet growing client demand for the must-have market intelligence that drives critical business decisions,” said Rob van den Bergh, CEO of the Dutch company, in a statement.

The merged company will be headed by van den Bergh as CEO, with David Carlucci, CEO of IMS, as deputy CEO and chief operating officer.

IMS is focused primarily on pharma market information, tracking more than 1 million brands of prescription drugs on a daily basis, which amounts to more than 70% of all worldwide sales, including 90% of U.S. sales.

In a conference call, van den Bergh said his company is “confident” it can achieve at least EUR 85 million in synergistic cost savings and EUR 135 million in new revenues by the third year post-merger.

In other dealmaking news:

• AMS Homecare (Vancouver, British Columbia) reported that it has acquired exclusive distribution rights to sell Totaltrak’s (Tampa, Florida) product line to the healthcare industry in Canada. In addition, AMS will have the first right of refusal to acquire the exclusive distribution rights to sell that company’s product line to the healthcare industry in the U.S.

AMS Homecare is a national provider of mobility products, durable medical products and patient monitoring technology.

“The distribution rights allow the company to continue to assemble a range of monitoring assets to further enhance and expand our IER Systems Division,” said Harj Gill, CEO of AMS.

Totaltrak is an asset management company using radio frequency identification and patent-pending multiple range identification technologies, global positioning technologies and advanced programming to create “total asset management systems.”

• StemCell Pharma (Las Vegas) acquired exclusive rights for two types of products containing placenta-derived stem cells. The first is a line of anti-aging/aging control products in oral form and the second product involves cosmetics from face creams to hair products. Terms of the deals were not disclosed.

Placenta blood contains totipotent stem cells (cells that can give rise to a fully/total functional new organism). They can engineer and repair any damaged tissue or organ. They are different from pluripotent stem cells that can only differentiate into any cell type of the human body, and multipotent stem cells limited to giving rise to cells that are specialized for a particular function, for example, blood stem cells give rise only to red blood cells, white blood cells and platelets, or skin stem cells that give rise to the various types of skin cells.

Placenta blood has all types of stem cells, totipotent, pluripotent, and multipotent, plus nutrients, hormones, and others needed for the development of the future baby.

The present research is gearing toward extracting various types of stem cells from placenta, umbilical cord, embryos, bone marrow, nervous tissues, fat, etc., cultures them and coax them into becoming new blood, nerves, skin, repair hearts, pancreases and others.

No Comments